Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate effects of magnesium sulfate on onset and duration of low dose rocuronium, intubation condition and surgical condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent

NCT03890406

Laparoscopy General Anesthesia Neuromuscular Blockade

COMPLETED NA

The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children

NCT03132701

Emergence Delirium

COMPLETED NA

Effectiveness of Deep Versus Moderate Neuromuscular Blockade

NCT03266419

Neuromuscular Blockade

COMPLETED NA

Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia

NCT01460563

Cerebral Aneurysm

UNKNOWN NA

Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade

NCT06794450

Neuromuscular Blocking Agents Reversal of Neuromuscular Blockade Recovery Time

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Observation of Neuromuscular Block Intubation Condition Surgical Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard dose rocuronium group

pretreatment of saline 100ml and rocuronium 0.6 mg/kg

Group Type ACTIVE_COMPARATOR

saline

Intervention Type DRUG

Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia

low dose rocuronium group

pretreatment of saline 100ml and rocuronium 0.45 mg/kg

Group Type ACTIVE_COMPARATOR

saline

Intervention Type DRUG

Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia

low dose rocuronium plus magnesium group

pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg

Group Type ACTIVE_COMPARATOR

magnesium sulfate 30 mg/kg

Intervention Type DRUG

Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

magnesium sulfate 30 mg/kg

Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia

Intervention Type DRUG

saline

Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-75 yr American Society of Anesthesiologists physical status 1 or 2, BMI of 20-24.9 kg/m2 scheduled for elective laryngeal microsurgery

Exclusion Criteria

* severe respiratory or cardiac disease hepatic or renal function impairment neuromuscular disease on medications affecting neuromuscular function with known allergy to the drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No